Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand

Praditsitthikorn, Naiyana; Teerawattananon, Yot; Tantivess, Sripen; Limwattananon, Supon; Riewpaiboon, Arthorn; Chichareon, Saibua; Ieumwananonthachai, Nantakan; Tangcharoensathien, Viroj

doi:10.2165/11586560-000000000-00000

Cited by 55 publications

(78 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, HPV vaccine has been promoted during the last few years in Thailand. These two interventions are expected to reduce the incidence of cervical cancer (Praditsitthikorn et al, 2011) and that is likely reflected in our data.…”

Section: Discussionmentioning

confidence: 69%

Numbers of New Cases and Trends of Cancer 1993-2012: Srinagarind Hospital Based Population, Khon Kaen, North-East Thailand

Wirasorn

Suwanrungruag²,

Wiangnon³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 69%

Numbers of New Cases and Trends of Cancer 1993-2012: Srinagarind Hospital Based Population, Khon Kaen, North-East Thailand

Wirasorn

Suwanrungruag²,

Wiangnon³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Thailand is one of the only LMICs to have a locally established threshold (100,000 Baht in 2008 values) as a guide for decision making. This local threshold is below the thresholds put forward by the WHO and has been used as a reference value in some vaccine evaluations for Thailand [13]. However, other studies evaluating HPV and rotavirus vaccination in Thailand have used the 'WHO-CHOICE thresholds' instead of the local threshold [14][15][16].…”

Section: How Have the Who-choice Thresholds Been Used For Vaccines Inmentioning

confidence: 99%

Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines

2014

View full text Add to dashboard Cite

The World Health Organization's CHOosing Interventions that are Cost Effective (WHO-CHOICE) thresholds for averting a disability-adjusted life-year of one to three times per capita income have been widely cited and used as a measure of cost effectiveness in evaluations of vaccination for low-and middle-income countries (LMICs). These thresholds were based upon criteria set out by the WHO Commission on Macroeconomics and Health, which reflected the potential economic returns of interventions. The CHOICE project sought to evaluate a variety of health interventions at a subregional level and classify them into broad categories to help assist decision makers, but the utility of the thresholds for within-country decision making for individual interventions (given budgetary constraints) has not been adequately explored. To examine whether the 'WHO-CHOICE thresholds' reflect funding decisions, we examined the results of two recent reviews of cost-effectiveness analyses of human papillomavirus and rotavirus vaccination in LMICs, and we assessed whether the results of these studies were reflected in funding decisions for these vaccination programmes. We found that in many cases, programmes that were deemed cost effective were not subsequently implemented in the country. We consider the implications of this finding, the advantages and disadvantages of alternative methods to estimate thresholds, and how cost perspectives and the funders of healthcare may impact on these choices.

show abstract

“…As a result, it is important to consider the findings of budget impact analyses for the various influenza vaccination strategies under consideration. There may also be locally established thresholds for decision‐makers which should be considered (as in Thailand42). The estimation of thresholds for LMICs is an area of research that is evolving quickly, and new recommendations may soon emerge.…”

Section: Estimating and Presenting Results Of The Economic Evaluationmentioning

confidence: 99%

WHO guide on the economic evaluation of influenza vaccination

Newall

Chaiyakunapruk

Lambach

et al. 2017

Influenza Resp Viruses

View full text Add to dashboard Cite

Influenza is responsible for substantial morbidity and mortality across the globe, with a large share of the total disease burden occurring in low‐ and middle‐income countries (LMICs). There have been relatively few economic evaluations assessing the value of seasonal influenza vaccination in LMICs. The purpose of this guide is to outline the key theoretical concepts and best practice in methodologies and to provide guidance on the economic evaluation of influenza vaccination in LMICs. It outlines many of the influenza vaccine‐specific challenges and should help to provide a framework for future evaluations in the area to build upon.

show abstract

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand

Abstract: The results suggest that controlling cervical cancer by increasing the numbers of women accepting the VIA and Pap smear screening as routine and by improving the performance of the existing screening programmes is the most cost-effective policy option in Thailand.

Cited by 55 publications

References 26 publications

Numbers of New Cases and Trends of Cancer 1993-2012: Srinagarind Hospital Based Population, Khon Kaen, North-East Thailand

Numbers of New Cases and Trends of Cancer 1993-2012: Srinagarind Hospital Based Population, Khon Kaen, North-East Thailand

Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines

WHO guide on the economic evaluation of influenza vaccination

Contact Info

Product

Resources

About